Navigation Links
DendriMed scientist seeks to fast-track success
Date:3/27/2008

Gleaning critical technical knowledge and building important international relationships is top of the agenda for rising Australian biotechnology star, DendriMed Research Director Dr Raisa Monteiro, when she meets with leading industry figures in the US in May.

One of two Australian life scientists chosen from a highly competitive field of candidates for the prestigious 2008 Advancing BioBusiness Award, Russian-born Dr Monteiro will attend the worlds largest biotechnology meeting, the Biotechnology Industry Organisation (BIO) convention, which attracts over 22,000 delegates from around the globe.

A tailored program of meetings will also be scheduled for her with leading American players including venture capital firms, research institutes, biotechnology entrepreneurs and biopharmaceutical companies, to help build valuable international networks, knowledge and collaborations.

The Advancing BioBusiness Award is an innovative scheme by Merck Sharp & Dohme and Advance, a dynamic, diverse global community of Australian professionals overseas committed to advancing Australia and Australians.

Russian-born Dr Monteiro, whose late father worked with the team that successfully cloned Dolly the sheep, is one of Australias brightest hopes in biotechnology, having moved here in 2002 with her Australian husband, an academic at the University of Queensland. During her 10-year career as a polymer scientist in America and Australia, she has notched up seven US patents with another three applications pending for technology she conceived and developed.

Now at DendriMed, her focus has turned to using smart polymer-based nanostructures to deliver drugs to targeted tissue and organs.

Dr Monteiro said through the Advancing BioBusiness Award, she wants to overcome the tyranny of distance and open up business opportunities in the global marketplace by meeting face-to-face with US biopharmaceutical heavyweights.

Successfully commercialising Australian technologies is not just about the merit of your science, but also knowing the right people, Dr Monteiro said. Networking with major players in the US makes distances shorter and bridges easier to cross.

Senator Kim Carr, Minister for Innovation, Industry, Science and Research, said: "The Advancing BioBusiness Award complements the Rudd Government's policy of promoting innovation and commercialisation in the biotechnology and pharmaceutical sector, encouraging closer links between Australian biotech and global pharmaceutical companies, and helping Australian biotechs access global supply chains."

Dr Phil Kearney, Merck Sharp & Dohmes manager for external scientific affairs, said Australia is recognised for its excellence in medical research and its vigorous and creative biotechnology industry. However the number of drug development projects which reach advanced clinical development is only a quarter of what would be predicted on the basis of our output in scientific literature.

By immersing two of our top biotechnology people in successful commercial research centres in the United States, and providing them with opportunities to share their learning back at home, we aim to build a stronger Australian capability to win in this highly competitive global knowledge market, he said.

The other recipient of the 2008 Advancing BioBusiness Award is Dr Christopher Wraight, Research Director, Antisense Therapeutics Ltd.


'/>"/>

Contact: Jackie Crossman
61-293-610-519
Research Australia
Source:Eurekalert

Related medicine news :

1. Scientists Isolate Organism That Causes Disfiguring Tropical Disease
2. Brain scientist shedding light on learning, memory
3. Scientists uncover how superbug Staph aureus resists our natural defenses
4. Signaling protein helps limit damage in heart attack, Jefferson scientists show
5. Scripps Florida scientists develop a process to disrupt hepatitis C virion production
6. Scientists see Norwalk virus Achilles heel
7. 52 minority scientists receive travel fellowships to Experimental Biology 2008
8. IUPUI scientists report first 3-D view of anti-cancer agent
9. Scientists successfully awaken sleeping stem cells
10. Bonn scientists discover new hemoglobin type
11. Scientists shine new light on inflammatory diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: